Emotional Design in Regulated Industries: Why the Most Effective Brand Redesigns of 2024–2026 Started With a Neuroscience Brief, Not a Mood Board

TLDR: The regulated-industry rebrands that outperformed market benchmarks between 2022 and 2024 share one structural feature: the neuroscience brief arrived before the mood board, embedding compliance constraints as design inputs and producing emotionally potent identities that passed review intact, at full creative strength.

The conventional brand redesign in a regulated industry follows a reliable sequence. The creative brief goes to the agency. The agency develops concepts, often sourced from mood boards. The finished creative reaches the medical-legal-regulatory (MLR) team or external counsel, whose function is to identify anything that could constitute a promotional claim, an unsubstantiated health assertion, or a misleading impression. By the time a visual identity reaches market, the emotional charge that might have earned attention and encoded memory traces has been systematically reduced toward a defensible minimum.

The Sanofi, Boehringer Ingelheim, Novartis, and UBS redesigns of 2022 through 2024 ran a different sequence. Each began with structured research before any visual concept existed: stakeholder interviews, emotional gap mapping, values analysis. Compliance parameters entered the brief before the creative agency did. The emotional territory was selected specifically because it remained compliant by construction. The result was emotionally resonant corporate identity that survived review intact.

The structural reason that approach outperformed the mood-board-first model is both mechanistic and instructive.

System 1 Processing Sets the Gate Before Rational Analysis Begins

Daniel Kahneman’s dual-process framework, formalised in Thinking, Fast and Slow (Farrar, Straus and Giroux, 2011), distinguishes System 1 cognition (fast, automatic, emotional) from System 2 cognition (deliberate, effortful, rational). Brand recognition, trust signals, and emotional valence are processed by System 1 before System 2 has engaged. A patient selecting a medication brand, or a chief financial officer (CFO) evaluating a financial institution, passes through a subconscious gate before rational consideration begins. That gate is set by emotional and visual cues.

For regulated industries, this finding carries a direct commercial implication. The emotional and visual signature of a brand determines whether it passes the System 1 filter, the subconscious threshold that governs whether the brand enters the consideration set at all. A brand identity stripped of emotional content through compliance review forfeits that filter advantage and requires the prospective client or patient to engage System 2 deliberation from first exposure. Most human decision-making is structured to avoid that additional cognitive load.

The neurochemical substrate of trust operates at the same pre-rational level. Paul J. Zak of Claremont Graduate University, in a randomised double-blind trial conducted with Barraza, Hu, Terris and Wang, demonstrated that oxytocin elevates perceived brand competence and social-emotional engagement, with participants willing to pay significantly more for brands encountered under oxytocin elevation (PLOS ONE, 2021). Zak’s broader research on trust, published in the Harvard Business Review, documents that organisations structurally designed to generate trust outperform low-trust peers on energy, engagement, and productivity measures. Social-emotional language in response to brand stimuli increased, with references to family rising 286 percent and references to friends 227 percent above baseline. Perceived competence, the primary evaluative criterion in both pharmaceutical and financial services selection, is in measurable part a neurochemical outcome of emotional brand design.

Memory encoding follows the same pathway. Florin Dolcos, Kevin LaBar and Roberto Cabeza established that amygdala activation at the moment of encoding predicts subsequent recall of emotional stimuli (Journal of Neuroscience, 2006). Emotionally charged brand encounters create stronger and longer-lasting memory traces than neutral ones. A brand identity designed for emotional resonance is simultaneously engineered for memorability.

The commercial corollary is documented in the Institute of Practitioners in Advertising (IPA) Databank. In The Long and the Short of It (Binet and Field, 2013), analysis across approximately 1,000 case studies established that emotional campaigns are almost twice as likely to produce top-box profit growth compared with rational ones. The optimal investment allocation for financial services brands places emotional brand work at 70 to 80 percent of total marketing effort. The 2024 IPA Effectiveness Awards confirmed that emotion-led campaigns built on trust drove measurable business results across finance and pharmaceutical categories. Nurofen’s pivot to an emotion-led platform anchored in the gender pain gap reversed declining sales. Kantar finds that digital advertisements evoking strong emotions are four times more likely to drive brand equity in pharmaceutical digital environments, and three times more likely to lift brand preference.

MLR Review Was Built for Product Claims, and It Applies That Discipline to Everything

The compliance frameworks governing regulated communications serve a legitimate public function. The United States Food and Drug Administration (FDA) issued final rules in November 2023 requiring that the major statement in direct-to-consumer (DTC) television and radio advertisements appear in a clear, conspicuous, and neutral manner, targeting emotional techniques that can obscure risk communication. The FDA’s Office of Prescription Drug Promotion (OPDP) issued enforcement letters against campaigns that amplified misleading impressions. For European Union markets, the European Medicines Agency (EMA) applies parallel requirements, with the same structural emphasis on separating promotional from identity communications. The UK Financial Conduct Authority (FCA) requires under Conduct of Business Sourcebook (COBS) 4.2 that financial promotions be fair, clear and balanced. The FCA’s March 2024 guidance FG24/1 extended standalone-compliance requirements to image-based social media content. In Switzerland, the Swiss Financial Market Supervisory Authority (FINMA) applies comparable obligations to financial communications.

These frameworks are calibrated for product promotion. OPDP’s authority covers prescription drug advertising; the FCA’s financial promotions regime governs commercial communications about financial products. Corporate identity, meaning the values, visual language, emotional posture and personality of the company, sits in a separate regulatory category. A corporate brand claim expressing accompaniment, craft, or optimism is assessed against a substantially different standard than a product efficacy claim.

The compliance bottleneck arises from a category error that is organisationally understandable. MLR teams, trained to apply conservative instinct to product communications, bring that same conservative instinct to corporate brand decisions. Kantar’s 2025 assessment of the pharmaceutical advertising environment observed that pharma brands frequently default to clinical tones and problem-solution formulas, limiting campaign impact even where emotional engagement would be legally permissible. Legal design commentary noted that design teams receive little creative freedom even for financial promotions online (Osborne Clarke), with that constraint extending in practice to identity work that falls outside promotional rules entirely, because the review process was built with product advertising in mind.

The structural outcome is a process designed to review finished product advertising for legal compliance, applied to corporate identity creative, producing emotional reduction regardless of whether that reduction is legally required.

The Sequence Inversion Is the Mechanism: Why the Neuro Brief Changes What Survives Review

The insight from the 2022 to 2024 regulated-brand redesigns is mechanistic. Starting with the neuroscience brief changes what enters compliance review, and therefore changes what exits it.

In the traditional sequence, the creative team develops emotional concepts driven by aesthetic intuition and mood boards. Those concepts reach MLR or legal review as finished executions. The review identifies emotional claims that could be construed as product efficacy claims, such as “miracle,” “will transform,” or “breakthrough,” and removes or qualifies them. The emotional charge is stripped from concepts built prior to any compliance input, with parameters arriving as external constraints at the review stage. The process is structurally adversarial because the creative and compliance functions optimised for different goals at separate stages.

The inversion changes the optimisation target from the outset. The neuroscience brief begins by identifying the emotional territory the brand requires: which emotional responses (trust, hope, accompaniment, mastery) are neurologically relevant to the target audience’s decision-making, and which of those territories fall clearly outside product-claim territory. That emotional mapping produces a brief that is simultaneously emotionally precise and compliance-resilient. The design team receives a mandate to execute within compliant emotional space, with compliance parameters as creative inputs at the brief stage.

This is the structural explanation for why Boehringer Ingelheim’s “Unwavering Optimism” platform survived MLR review with creative integrity intact while other pharma rebrands required significant compromise. The emotional territory (aspiration, perseverance, directional energy) was identified before visual development began, in part because it was demonstrably outside the OPDP and EMA drug advertising review scope. “Life forward” is an aspirational directional statement; it carries the emotional charge of hope with the structural form of a corporate values claim. The compliance review received a concept engineered to pass it.

Sanofi’s “miracles of science” framing illustrates the same mechanism at the individual word level. “Miracle” as a product claim is clinically indefensible. “Miracle” as a description of a patient’s felt experience of transformational medicine is an emotional observation about human experience, and a substantially different compliance question. That distinction was established before the design brief was written, which is why the internal legal challenge was resolved through contextual clarification rather than creative compromise.

UBS’s “Craft” platform was structured as an identity communication before the design agency received any brief, placing it outside the scope of both the FCA and FINMA promotional review frameworks from the outset. High-net-worth (HNW) and ultra-high-net-worth (UHNW) clients, post-merger research showed, value trust and human attention above abstract performance claims. “Craft” addressed that neurological priority in a form that placed it outside financial promotions review scope from the outset.

Gerald Zaltman’s research at Harvard Business School, establishing that approximately 95 percent of consumer decision-making occurs at the subconscious level, provides the foundational rationale for why emotional territory selection must precede creative development. If 95 percent of the evaluative work happens before conscious deliberation, a brand identity optimised primarily for rational defensibility is built for the five percent of the decision.

Four Regulated-Brand Redesigns That Applied the Sequence (2022 to 2024)

The following cases are drawn from company press releases, agency case studies, and industry awards documentation. Each demonstrates the sequence inversion in practice: emotional platform defined before visual development, compliance constraints treated as design inputs from the briefing stage.

Three Frameworks Making the Neuro-First Brief Operational for Design Teams

The shift from mood-board-first to neuro-brief-first depends on operationalising neuroscience methods at the strategy stage rather than the evaluation stage. Three frameworks currently apply at brief stage in regulated-industry brand work.

A 2024 PRISMA-based meta-analysis of EEG studies in consumer behaviour, published in SAGE Open (Wang et al.), confirmed that EEG provides reliable, actionable measures of emotional arousal and attention that predict downstream brand preference, validating the physiological measurement layer that neuro-brief frameworks rely on. Neurons Inc deploys electroencephalography (EEG), eye-tracking, facial coding, and Implicit Association Testing (IAT) to brand design decisions before production commitments are made. The firm’s artificial intelligence (AI) prediction layer claims accuracy above 95 percent in predicting consumer emotional responses to brand stimuli before launch. Applied to regulated-industry branding, the framework tests emotional concepts against audience physiological response data before the design brief is finalised, precisely the sequence the 2022 to 2024 cases demonstrate. The firm’s ethics framework addresses the regulated-industry context directly, acknowledging the tension between persuasive emotional design and the disclosure obligations that govern regulated communications.

KMI Healthcare Marketing applies EEG, eye-movement tracking, and biometric measurement including pupillometry and blood volume pulse to test headlines, taglines, and visual concepts before the brand brief is finalised. The firm has applied this methodology to SummaCare and Summa Health System, healthcare organisations operating in the same regulated environment as the pharma cases reviewed here. The operating premise, that 90 percent of decisions occur in the subconscious, determines that the brief must speak to subconscious emotional response as its primary criterion. When the brief is built on that premise, the creative that results from it already addresses the 90 percent.

System1 Group’s Star Rating and Spike Rating framework measures emotional response to brand communications before final production decisions are made. In the firm’s financial services meta-analysis correlating emotional scores with sales effectiveness data, happiness emerges as the strongest single predictor of long-term brand growth. The practical application is a pre-production emotional assessment that identifies which creative directions carry brand-growth potential before investment is committed to visual development, giving compliance review a smaller target because only emotionally validated concepts proceed to execution.

The Brief Determines the Outcome: What Commissioning a Regulated Redesign in 2025 and 2026 Actually Requires

The lesson from the 2022 to 2024 cases is structural, practical, and available to any brand commissioning a redesign in the current period. The neuro-first sequence is a briefing protocol, a sequencing decision, and a stakeholder management choice. It requires the brand team to commission neurological and emotional research before engaging the creative agency, and to bring compliance representation into the brief stage rather than the review stage.

The practical outcome of compliance involvement at the brief stage is identification of compliant emotional territories before investment in visual concepts built in territories that will require reduction. Sanofi’s legal challenge to “miracle” was addressed before visual development began. UBS’s “Craft” platform was structured as an identity communication before the design agency received any brief. Boehringer Ingelheim’s “Life forward” was constructed around the OPDP and EMA scope boundary before Interbrand began visual work. In each case, the compliance function’s constraints became design parameters rather than creative reductions.

The sequence inversion also changes the organisational role of neuroscience data. When the emotional brief precedes the creative brief, the neuroscience assessment acquires the authority to direct creative strategy: it determines which emotional territory the brand will occupy. In the traditional sequence, neuroscience evaluation (when commissioned at all) assesses finished creative against emotional criteria at a point where revision is costly and compliance review has already constrained the available emotional options. The neuro brief at stage one is an expansion of creative scope; neuroscience evaluation at stage four is an audit of what survived the process.

Kantar’s 2025 assessment identified the pattern clearly: brands defaulting to clinical tones and problem-solution formulas did so because their development process sequence produced that outcome, rather than because emotional engagement was legally prohibited. The compliance review reduced what the brief and creative process generated in advance of compliance input. Addressing the sequence addresses the outcome.

Kainjoo’s practice in neuro-led brand strategy for regulated industries grounds this structural logic in execution: the emotional brief, the compliance map, and the neuroscience assessment belong at stage one, before any visual concept exists. The four cases reviewed here confirm that the brands setting the commercial and creative standard in pharma and financial services are those that made that sequencing decision. The mood board is a tool for the second stage. The neuro brief is the first.

References

1. Kahneman, D. (2011). Thinking, Fast and Slow. Farrar, Straus and Giroux. https://www.farrarstrausandgiroux.com/books/thinking-fast-and-slow/
2. Barraza, J.A., Hu, J., Terris, E.T., Wang, Y. and Zak, P.J. (2021). “Oxytocin increases perceived competence and social-emotional engagement with brands.” PLOS ONE 16(11): e0260589. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0260589
3. Zak, P.J. (2017). “The Neuroscience of Trust.” Harvard Business Review. https://hbr.org/2017/01/the-neuroscience-of-trust
4. Dolcos, F., LaBar, K.S. and Cabeza, R. (2006). Amygdala activation and subsequent memory for emotional stimuli. Journal of Neuroscience. https://www.jneurosci.org/content/26/9/2564
5. Wang, F. et al. (2024). “Neuro-Insights in Marketing Research: A PRISMA-Based Analysis of EEG Studies on Consumer Behavior.” SAGE Open 2024. https://journals.sagepub.com/doi/full/10.1177/21582440241305365
6. Binet, L. and Field, P. (2013). The Long and the Short of It: Balancing Short and Long-Term Marketing Strategies. IPA. https://ipa.co.uk/knowledge/publications-reports/the-long-and-short-of-it-balancing-short-and-long-term-marketing-strategies/
7. IPA (2024). “Five Winning Strategies from the 2024 IPA Effectiveness Awards.” https://ipa.co.uk/knowledge/ipa-blog/five-winning-strategies-from-the-2024-ipa-effectiveness-awards/
8. Kantar (2025). “Pharma Advertising at a Crossroads.” https://www.kantar.com/north-america/inspiration/advertising-media/pharma-advertising-at-a-crossroads
9. Kantar. “Digital Ads Which Evoke Strong Emotions Are Four Times More Likely to Drive Brand Equity.” https://www.kantar.com/north-america/company-news/digital-ads-which-evoke-strong-emotions-are-four-times-more-likely-to-drive–brand-equity
10. Sanofi (2022). “Sanofi Unveils Bold New Brand Identity.” Press release, February 2022. https://www.sanofi.com/en/media-room/press-releases/2022/2022-02-03-16-00-00-2378702
11. FutureBrand. “Sanofi Brand Redesign.” Case study. https://www.futurebrand.com/our-work/sanofi
12. Campaign Asia (2022). “Behind the Scenes of Pharmaceutical Giant Sanofi’s Rebranding.” https://www.campaignasia.com/article/behind-the-scenes-of-pharmaceutical-giant-sanofis-rebranding/475626
13. Fierce Pharma (2024). “Sanofi’s New Corporate Look Sees It Become 2024 REBRAND 100 Global Award Winner.” https://www.fiercepharma.com/marketing/sanofis-new-corporate-look-sees-it-become-2024-rebrand-100-global-award-winner
14. Boehringer Ingelheim (2023). “Life Forward: Boehringer Ingelheim Company Brand.” https://www.boehringer-ingelheim.com/about-us/life-forward-boehringer-ingelheim-company-brand
15. Interbrand (2023). “Life Forward: Relaunch of the Boehringer Ingelheim Corporate Brand.” https://interbrand.com/newsroom/life-forward-relaunch-of-the-boehringer-ingelheim-corporate-brand/
16. Fierce Pharma (2023). “Boehringer Clears the Blues to Go Green, Unveiling New Corporate Branding to Convey Unwavering Optimism.” https://www.fiercepharma.com/marketing/boehringer-clears-blues-go-green-unveiling-new-corporate-branding-convey-unwavering
17. Monotype (2023). “Custom Variable Font: Interbrand and Boehringer Forward.” https://www.monotype.com/resources/case-studies/custom-variable-font-interbrand-boehringer-forward
18. UBS (2024). “Banking Is Our Craft Campaign.” Press release, January 2024. https://www.ubs.com/global/en/media/display-page-ndp/en-20240123-craft.html
19. Prophet. “UBS: How Brand Defined a New Growth Era.” Case study. https://prophet.com/case-studies/ubs-how-brand-defined-new-growth-era/
20. LBBOnline. “UBS Banking Is Our Craft Campaign.” https://lbbonline.com/work/161400
21. MM+M (2023). “Novartis Rebrand: We’re With You.” https://www.mmm-online.com/home/channel/novartis-rebrand-were-with-you/
22. Novartis (2023). “Novartis: Our Next Era.” https://www.novartis.com/news/our-next-era
23. Federal Register (2023). “Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner.” https://www.federalregister.gov/documents/2023/11/21/2023-25428/direct-to-consumer-prescription-drug-advertisements-presentation-of-the-major-statement-in-a-clear
24. Latham and Watkins (2024). “FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising.” https://www.lw.com/en/insights/fda-begins-crackdown-on-direct-to-consumer-pharmaceutical-advertising
25. Financial Conduct Authority (2024). “FG24/1: Finalised Guidance on Financial Promotions in Social Media.” https://www.fca.org.uk/publications/finalised-guidance/fg24-1-finalised-guidance-financial-promotions-social-media
26. Osborne Clarke. “UK FCA Guidance Leaves Little Creative Freedom for Financial Promotions Online.” https://www.osborneclarke.com/insights/uk-fca-guidance-leaves-little-creative-freedom-for-financial-promotions-online
27. Neurons Inc. “Neuromarketing Applications: Branding.” https://www.neuronsinc.com/neuromarketing/applications/branding
28. Zaltman, G. (2003). How Customers Think: Essential Insights into the Mind of the Market. Harvard Business School Press. Applied reference: https://www.neuronsinc.com/neuromarketing
29. KMI Healthcare Marketing. “Neuromarketing Services.” https://kmihealthcaremarketing.com/services/neuromarketing/
30. KMI Healthcare Marketing. “How Neuromarketing Can Improve Your Brand.” https://kmihealthcaremarketing.com/how-neuromarketing-can-improve-your-brand/
31. System1 Group. “Emotional Advertising in Financial Services: Driving Brand Growth.” https://system1group.com/blog/emotional-advertising-in-financial-services-driving-brand-growth